Teva to pay $27.6m to settle fraud charges
Both banks note that Dr. Jeremy Levin was instrumental in executing Bristol-Myers Squibb's successful “string of pearls” strategy.
Credit Suisse and Barclays Capital both believe that the appointment of Dr. Jeremy Levin as the next president and CEO of Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) indicates that more acquisitions of brand pharmaceutical companies are on the way.
Credit Suisse says, "One of the most obvious inferences from the selection of Dr. Levin is that Teva is seeking to do more branded pharma deals. Another possibility is that Teva is seeking someone to lead the company through a strategic redeployment of its product pipeline and portfolio, as the company’s branded pharma footprint evolves beyond the Cephalon acquisition and the decline of Copaxone." It noted, "Dr. Levin was instrumental in executing Bristol-Myers Squibb Inc's (NYSE: BMY) successful “string of pearls” strategy." This included split-off of Mead Johnson and sale of Convatec, and the acquisitions of Medarex and Zymogenetics.
Barclays says that the appointment of Dr Jeremy Levin to succeed Shlomo Yanai should help build investor confidence in the company's efforts to build its brand business. "We believe that Levin is a good choice for the job. His appointment clearly signals that Teva will remain acquisitive in building its brand business but at appropriate scale since Levin will likely attempt to recreate his "string of pearls" success. Indeed, this should alleviate investor concerns that Teva would make additional large acquisitions in order to achieve its 2015 guidance targets. In particular, we believe Levin will drive acquisitions in oncology, which has been a focus for Teva business development for some time, including the Cephalon acquisition. We believe Teva views oncology as having strategic importance since it will be a key market for biosimilars and is a market that doesn't require a large field force to promote products."
Barclays notes however, that Yanai's departure comes just ten days after Teva announced that Dr Robert Koremans would replace Dr Gerard van Odijk as President and CEO of Teva Europe. "The departure of two senior executives within two weeks would normally be a cause for some alarm, although these moves were apparently in the works for some time since Teva named replacements from outside the company immediately. Nevertheless, the extent of turnover at the senior executive level so soon after two major acquisitions - Cephalon (October 2011) and Ratiopharm (August 2010) - should not be taken lightly. Moreover, it's natural that Levin will want to build his own team, especially in the brand business, which could lead to additional management changes over the next 12-18 months."
Credit Suisse gives Teva an "Outperform" recommendation with a target price of $60, and Barclays gives it an "Equal weight" recommendation with a target price of $42.
Teva's share price rose 4.2% in early trading on Nasdaq today to $42.06, giving a market cap of $36 billion, after rising less than 0.1% on the TASE to NIS 160.70.
Published by Globes [online], Israel business news - www.globes-online.com - on January 3, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012
You comment was recieved and soon will be published.
Load more comments
The company does not admit to charges of paying a psychiatrist to prescribe Clozapine.
Dermatology co Foamix mulls Nasdaq IPO
The developer of foam-based dermatology treatments is seeking underwriters.
Can-Fite Biopharma raises $5m
The proceeds will finance clinical trials for psoriasis, glaucoma, and liver cancer treatments.
Teva switching Copaxone users to new dosage
"Bloomberg": Teva has switched 8.7% of Copaxone's multiple sclerosis patients to the 40 milligram dosage.
Immune Pharmaceuticals raises $11.7m on Nasdaq
The money raised will fund a Phase II trial of ulcerative colitis drug bertilmumab.
XTL Biopharma files to raise $40m on Nasdaq
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.